Aldosterone 'escape' vs 'breakthrough'

Aldosterone breakthrough does not alter central hemodynamics

INTRODUCTION Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are widely used in congestive heart failure and chronic kidney disease, but up to 40% of patients will experience aldosterone breakthrough, with aldosterone levels rising above pre-treatment levels after 6-12 months of renin-angiotensin-aldosterone system blockade. Aldosterone breakthrough has been associate...

Renin-angiotensin-aldosterone activation in heart failure, aldosterone escape.

mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite.

Aldosterone (Aldo) is a major sodium-retaining hormone that reduces renal sodium excretion and also stimulates sodium appetite. In the face of excess Aldo, the sodium-retaining action of this steroid is overridden by an adaptive regulatory mechanism, a phenomenon termed Aldo escape. The underlying mechanism of this phenomenon is not well defined but appeared to involve a number of natriuretic f...

Increased Blood Pressure, Aldosterone Activity, and Regional Differences in Renal ENaC Protein During Vasopressin-Escape Short title: MAP, Aldosterone, and ENaC in vasopressin escape by

The syndrome of inappropriate anti-diuretic hormone (SIADH) is associated with water retention and hyponatremia. The kidney adapts via a transient natriuresis and persistent diuresis, i.e., vasopressin escape. Previously, we showed an increase in the whole kidney abundance of aldosterone-sensitive proteins, the αand γ(70-kDa band) subunits of the epithelial sodium channel (ENaC) and the thiazid...

Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.

Aldosterone breakthrough during ACE inhibitor therapy has been reported. This study investigates changes in plasma aldosterone concentration (PAC) and its mechanism and effects on target organ damage during long-term angiotensin II type 1 (AT1) receptor antagonist (AT1A) therapy in hypertensive rats. An AT1A (candesartan, 1 mg/kg per day PO) was administered in stroke-prone spontaneously hypert...